Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States
Abstract Introduction In September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. This study evaluates the effectiveness of mRNA-1273.815, a 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine in preventing COVID-19-rela...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-12-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-024-01091-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571455658786816 |
|---|---|
| author | Amanda Wilson Neloufar Rahai Ekkehard Beck Elisha Beebe Brian Conroy Daina Esposito Priya Govil Hagit Kopel Tianyi Lu James Mansi Morgan A. Marks Katherine E. Mues Rohan Shah Michelle Skornicki Tianyu Sun Astra Toyip Mitra Yousefi David Martin Andre B. Araujo |
| author_facet | Amanda Wilson Neloufar Rahai Ekkehard Beck Elisha Beebe Brian Conroy Daina Esposito Priya Govil Hagit Kopel Tianyi Lu James Mansi Morgan A. Marks Katherine E. Mues Rohan Shah Michelle Skornicki Tianyu Sun Astra Toyip Mitra Yousefi David Martin Andre B. Araujo |
| author_sort | Amanda Wilson |
| collection | DOAJ |
| description | Abstract Introduction In September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. This study evaluates the effectiveness of mRNA-1273.815, a 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine in preventing COVID-19-related hospitalizations and medically attended COVID-19 in US adults aged ≥ 18 years. Methods This observational, matched cohort study used medical and pharmacy claims data from HealthVerity. Adults vaccinated with mRNA-1273.815 between September 12, 2023, and December 31, 2023, were followed through January 26, 2024. Vaccinated individuals were matched with individuals unvaccinated with any 2023–2024 COVID-19 vaccine on demographic and clinical characteristics. The primary and secondary outcomes were COVID-19 hospitalization and medically attended COVID-19, respectively. Inverse probability of treatment weighting and Cox proportional hazards regression were utilized to estimate vaccine effectiveness (VE). Results The study included 1,272,161 vaccinated individuals matched 1:1 with unvaccinated individuals, with a maximum follow-up of 128 (median 84) days. The VE against COVID-19 hospitalization was 51% (95% confidence interval [CI]: 48–54%). Subgroup analyses showed a VE of 56% (95% CI 51–61%) among adults ≥ 65 years and 46% (95% CI 39–52%) in immunocompromised adults. For medically attended COVID-19, the VE was 25% (95% CI 24–27%). Time-varying analyses showed that while VE declined over time, VE remained significant. Conclusion During the 2023–2024 respiratory season, the mRNA-1273.815 vaccine significantly protected against COVID-19-related hospitalizations and medically attended COVID-19 across diverse adult populations and demonstrated durability of the effect. These results support the continued use of updated COVID-19 vaccines to mitigate severe outcomes and maintain public health safety. |
| format | Article |
| id | doaj-art-860361cdc11f48f2b13533ebf5996fa3 |
| institution | Kabale University |
| issn | 2193-8229 2193-6382 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj-art-860361cdc11f48f2b13533ebf5996fa32025-02-02T12:35:14ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822024-12-0114119921610.1007/s40121-024-01091-1Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United StatesAmanda Wilson0Neloufar Rahai1Ekkehard Beck2Elisha Beebe3Brian Conroy4Daina Esposito5Priya Govil6Hagit Kopel7Tianyi Lu8James Mansi9Morgan A. Marks10Katherine E. Mues11Rohan Shah12Michelle Skornicki13Tianyu Sun14Astra Toyip15Mitra Yousefi16David Martin17Andre B. Araujo18Moderna, Inc.AetionModerna, Inc.AetionAetionModerna, Inc.AetionModerna, Inc.Moderna, Inc.Moderna, Inc.Moderna, Inc.AetionAetionAetionModerna, Inc.AetionModerna, Inc.Moderna, Inc.Moderna, Inc.Abstract Introduction In September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. This study evaluates the effectiveness of mRNA-1273.815, a 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine in preventing COVID-19-related hospitalizations and medically attended COVID-19 in US adults aged ≥ 18 years. Methods This observational, matched cohort study used medical and pharmacy claims data from HealthVerity. Adults vaccinated with mRNA-1273.815 between September 12, 2023, and December 31, 2023, were followed through January 26, 2024. Vaccinated individuals were matched with individuals unvaccinated with any 2023–2024 COVID-19 vaccine on demographic and clinical characteristics. The primary and secondary outcomes were COVID-19 hospitalization and medically attended COVID-19, respectively. Inverse probability of treatment weighting and Cox proportional hazards regression were utilized to estimate vaccine effectiveness (VE). Results The study included 1,272,161 vaccinated individuals matched 1:1 with unvaccinated individuals, with a maximum follow-up of 128 (median 84) days. The VE against COVID-19 hospitalization was 51% (95% confidence interval [CI]: 48–54%). Subgroup analyses showed a VE of 56% (95% CI 51–61%) among adults ≥ 65 years and 46% (95% CI 39–52%) in immunocompromised adults. For medically attended COVID-19, the VE was 25% (95% CI 24–27%). Time-varying analyses showed that while VE declined over time, VE remained significant. Conclusion During the 2023–2024 respiratory season, the mRNA-1273.815 vaccine significantly protected against COVID-19-related hospitalizations and medically attended COVID-19 across diverse adult populations and demonstrated durability of the effect. These results support the continued use of updated COVID-19 vaccines to mitigate severe outcomes and maintain public health safety.https://doi.org/10.1007/s40121-024-01091-1MRNA-1273.815COVID-19 vaccineHospitalizationMedically attended COVID-19Vaccine effectiveness |
| spellingShingle | Amanda Wilson Neloufar Rahai Ekkehard Beck Elisha Beebe Brian Conroy Daina Esposito Priya Govil Hagit Kopel Tianyi Lu James Mansi Morgan A. Marks Katherine E. Mues Rohan Shah Michelle Skornicki Tianyu Sun Astra Toyip Mitra Yousefi David Martin Andre B. Araujo Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States Infectious Diseases and Therapy MRNA-1273.815 COVID-19 vaccine Hospitalization Medically attended COVID-19 Vaccine effectiveness |
| title | Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States |
| title_full | Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States |
| title_fullStr | Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States |
| title_full_unstemmed | Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States |
| title_short | Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States |
| title_sort | evaluating the effectiveness of mrna 1273 815 against covid 19 hospitalization among adults aged ≥ 18 years in the united states |
| topic | MRNA-1273.815 COVID-19 vaccine Hospitalization Medically attended COVID-19 Vaccine effectiveness |
| url | https://doi.org/10.1007/s40121-024-01091-1 |
| work_keys_str_mv | AT amandawilson evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT neloufarrahai evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT ekkehardbeck evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT elishabeebe evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT brianconroy evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT dainaesposito evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT priyagovil evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT hagitkopel evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT tianyilu evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT jamesmansi evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT morganamarks evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT katherineemues evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT rohanshah evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT michelleskornicki evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT tianyusun evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT astratoyip evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT mitrayousefi evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT davidmartin evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates AT andrebaraujo evaluatingtheeffectivenessofmrna1273815againstcovid19hospitalizationamongadultsaged18yearsintheunitedstates |